Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis-Reference-Cited by-同舟云学术

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis

Published:2019-07 Issue: Volume:133 Page:96-102
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Awad Mark M.,Leonardi Giulia C.,Kravets Sasha,Dahlberg Suzanne E.,Drilon Alexander,Noonan Sinead A.,Camidge D. Ross^ORCID,Ou Sai-Hong I.,Costa Daniel B.,Gadgeel Shirish M.,Steuer Conor E.,Forde Patrick M.,Zhu Viola W.^ORCID,Fukuda Yoko,Clark Jeffrey W.,Jänne Pasi A.,Mok Tony,Sholl Lynette M.,Heist Rebecca S.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference24 articles.

1. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009

2. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol.,2011

3. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations;Sequist;J. Clin. Oncol.,2013

4. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N. Engl. J. Med.,2014

5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations;European Journal of Cancer;2024-08

2. Lung cancer associated with an activating mutation in the 14th exon of the MET gene;Meditsinskiy sovet = Medical Council;2024-07-25

3. A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases;International Journal of Molecular Sciences;2024-06-26

4. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study;Future Oncology;2024-04-22

5. Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK;Targeted Oncology;2024-03